End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.01 CNY | +0.08% |
|
-1.81% | -15.46% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.46% | 2.09B | D+ | ||
+61.22% | 846B | C+ | ||
+40.18% | 628B | B | ||
-4.66% | 360B | C+ | ||
+16.77% | 322B | B- | ||
+8.50% | 297B | C+ | ||
+14.13% | 240B | B+ | ||
+17.85% | 223B | B- | ||
+2.74% | 224B | A+ | ||
+11.68% | 173B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000739 Stock
- Ratings Apeloa Pharmaceutical Co.,Ltd